EUROFINS CEREP-REGR (ALECR.PA) Stock Fundamental Analysis
EPA:ALECR • FR0013256518
16800 EUR
-1800 (-9.68%)
Last: Feb 12, 2026, 07:00 PM
Taking everything into account, ALECR scores 4 out of 10 in our fundamental rating. ALECR was compared to 18 industry peers in the Life Sciences Tools & Services industry. ALECR has an average financial health and profitability rating. ALECR has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
- In the past year ALECR was profitable.
- Each year in the past 5 years ALECR has been profitable.
- In the past 5 years ALECR always reported negative operating cash flow.
1.2 Ratios
- ALECR has a better Return On Assets (9.29%) than 88.89% of its industry peers.
- ALECR's Return On Equity of 10.82% is in line compared to the rest of the industry. ALECR outperforms 55.56% of its industry peers.
- ALECR has a Return On Invested Capital of 5.81%. This is in the lower half of the industry: ALECR underperforms 61.11% of its industry peers.
- ALECR had an Average Return On Invested Capital over the past 3 years of 8.88%. This is in line with the industry average of 9.81%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.29% | ||
| ROE | 10.82% | ||
| ROIC | 5.81% |
ROA(3y)11.69%
ROA(5y)12.73%
ROE(3y)14.25%
ROE(5y)16.06%
ROIC(3y)8.88%
ROIC(5y)10.64%
1.3 Margins
- The Profit Margin of ALECR (16.86%) is better than 88.89% of its industry peers.
- ALECR's Profit Margin has improved in the last couple of years.
- ALECR's Operating Margin of 12.72% is on the low side compared to the rest of the industry. ALECR is outperformed by 61.11% of its industry peers.
- ALECR's Operating Margin has declined in the last couple of years.
- ALECR has a Gross Margin of 85.67%. This is amongst the best in the industry. ALECR outperforms 100.00% of its industry peers.
- In the last couple of years the Gross Margin of ALECR has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.72% | ||
| PM (TTM) | 16.86% | ||
| GM | 85.67% |
OM growth 3Y-22.69%
OM growth 5Y-3.77%
PM growth 3Y-8.91%
PM growth 5Y4.87%
GM growth 3Y-0.31%
GM growth 5Y12.87%
2. Health
2.1 Basic Checks
- Compared to 1 year ago, ALECR has about the same amount of shares outstanding.
- ALECR has more shares outstanding than it did 5 years ago.
- ALECR has a worse debt/assets ratio than last year.
2.2 Solvency
- An Altman-Z score of 11.85 indicates that ALECR is not in any danger for bankruptcy at the moment.
- With an excellent Altman-Z score value of 11.85, ALECR belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
- A Debt/Equity ratio of 0.00 indicates that ALECR is not too dependend on debt financing.
- With an excellent Debt to Equity ratio value of 0.00, ALECR belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 11.85 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- A Current Ratio of 7.27 indicates that ALECR has no problem at all paying its short term obligations.
- ALECR's Current ratio of 7.27 is amongst the best of the industry. ALECR outperforms 100.00% of its industry peers.
- ALECR has a Quick Ratio of 6.83. This indicates that ALECR is financially healthy and has no problem in meeting its short term obligations.
- ALECR has a better Quick ratio (6.83) than 100.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.27 | ||
| Quick Ratio | 6.83 |
3. Growth
3.1 Past
- The earnings per share for ALECR have decreased by -6.41% in the last year.
- ALECR shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -3.78% yearly.
- Looking at the last year, ALECR shows a decrease in Revenue. The Revenue has decreased by -7.94% in the last year.
- ALECR shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.22% yearly.
EPS 1Y (TTM)-6.41%
EPS 3Y-28.46%
EPS 5Y-3.78%
EPS Q2Q%-2.25%
Revenue 1Y (TTM)-7.94%
Revenue growth 3Y-1.31%
Revenue growth 5Y5.22%
Sales Q2Q%-8.7%
3.2 Future
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 23.50, ALECR is valued on the expensive side.
- ALECR's Price/Earnings ratio is in line with the industry average.
- When comparing the Price/Earnings ratio of ALECR to the average of the S&P500 Index (27.19), we can say ALECR is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.5 | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
- No dividends for ALECR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
EPA:ALECR (2/12/2026, 7:00:00 PM)
16800
-1800 (-9.68%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap168.00M
Revenue(TTM)41.00M
Net Income(TTM)7.25M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.5 | ||
| Fwd PE | N/A | ||
| P/S | 3.91 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.51 | ||
| P/tB | 2.59 | ||
| EV/EBITDA | N/A |
EPS(TTM)715
EY4.26%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS4300
BVpS6700
TBVpS6476
PEG (NY)N/A
PEG (5Y)N/A
Graham Number10382
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.29% | ||
| ROE | 10.82% | ||
| ROCE | 7.94% | ||
| ROIC | 5.81% | ||
| ROICexc | 5.81% | ||
| ROICexgc | 6% | ||
| OM | 12.72% | ||
| PM (TTM) | 16.86% | ||
| GM | 85.67% | ||
| FCFM | N/A |
ROA(3y)11.69%
ROA(5y)12.73%
ROE(3y)14.25%
ROE(5y)16.06%
ROIC(3y)8.88%
ROIC(5y)10.64%
ROICexc(3y)10.25%
ROICexc(5y)11.89%
ROICexgc(3y)10.71%
ROICexgc(5y)12.51%
ROCE(3y)12.09%
ROCE(5y)14.49%
ROICexgc growth 3Y-34.97%
ROICexgc growth 5Y-16.9%
ROICexc growth 3Y-34.63%
ROICexc growth 5Y-16.09%
OM growth 3Y-22.69%
OM growth 5Y-3.77%
PM growth 3Y-8.91%
PM growth 5Y4.87%
GM growth 3Y-0.31%
GM growth 5Y12.87%
F-ScoreN/A
Asset Turnover0.55
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 7.27 | ||
| Quick Ratio | 6.83 | ||
| Altman-Z | 11.85 |
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.41%
EPS 3Y-28.46%
EPS 5Y-3.78%
EPS Q2Q%-2.25%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-7.94%
Revenue growth 3Y-1.31%
Revenue growth 5Y5.22%
Sales Q2Q%-8.7%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-33.62%
EBIT growth 3Y-23.7%
EBIT growth 5Y1.26%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A
EUROFINS CEREP-REGR / ALECR.PA FAQ
What is the ChartMill fundamental rating of EUROFINS CEREP-REGR (ALECR.PA) stock?
ChartMill assigns a fundamental rating of 4 / 10 to ALECR.PA.
Can you provide the valuation status for EUROFINS CEREP-REGR?
ChartMill assigns a valuation rating of 1 / 10 to EUROFINS CEREP-REGR (ALECR.PA). This can be considered as Overvalued.
How profitable is EUROFINS CEREP-REGR (ALECR.PA) stock?
EUROFINS CEREP-REGR (ALECR.PA) has a profitability rating of 5 / 10.
What are the PE and PB ratios of EUROFINS CEREP-REGR (ALECR.PA) stock?
The Price/Earnings (PE) ratio for EUROFINS CEREP-REGR (ALECR.PA) is 23.5 and the Price/Book (PB) ratio is 2.51.